CERS Stock - Cerus Corp.

CERS Stock Chart

CERS Profile

Cerus Corporation operates at the forefront of biomedical products with a dedicated focus on advancing blood safety through its innovative INTERCEPT Blood System. This proprietary technology is designed to control biological replication and significantly reduce blood-borne pathogens in donated blood components intended for transfusion. Cerus offers a comprehensive suite of INTERCEPT Blood Systems tailored for platelets, plasma, red blood cells, and Cryoprecipitation. These systems effectively inactivate pathogens, ensuring enhanced safety and efficacy in transfusion medicine.

Headquartered in Concord, California, Cerus Corporation markets its INTERCEPT Blood Systems globally, including in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and beyond. The company distributes its platelet and plasma systems through a combination of direct sales channels and strategic partnerships with distributors. Txrough continuous innovation and rigorous research, Cerus remains committed to pioneering solutions that address critical challenges in blood transfusion therapy, thereby safeguarding patients and healthcare providers worldwide.

Founded in 1991, Cerus Corporation has established itself as a leader in blood safety technology, driven by a mission to improve patient outcomes and public health. Beyond its product offerings, the company maintains a steadfast dedication to advancing medical science and fostering partnerships across the global healthcare community. With a strong foundation in biotechnology and a proactive approach to regulatory compliance, Cerus continues to set industry standards in transfusion medicine safety and efficacy.

CERS Revenue Chart

CERS Earnings

Analyst Ratings